Όλο το DSpace

Πλοήγηση ανά Θέμα "event free survival"

Αποτελέσματα 1-7 από 7

    • Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis 

      Gatselis N.K., Goet J.C., Zachou K., Lammers W.J., Janssen H.L.A., Hirschfield G., Corpechot C., Lindor K.D., Invernizzi P., Mayo M.J., Battezzati P.M., Floreani A., Pares A., Lygoura V., Nevens F., Mason A.L., Kowdley K.V., Ponsioen C.Y., Bruns T., Thorburn D., Verhelst X., Harms M.H., van Buuren H.R., Hansen B.E., Dalekos G.N., Global Primary Biliary Cholangitis Study Group (2020)
      Background & Aims: Patients usually receive a diagnosis of primary biliary cholangitis (PBC) at an early stage, based on biochemical analyses. We investigated the proportion of patients who progress to moderate or advanced ...

    • Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis 

      Müller T., Alberts R., De Vries E.M.G., Goode E.C., Jiang X., Sampaziotis F., Rombouts K., Böttcher K., Folseraas T., Weismüller T.J., Mason A.L., Wang W., Alexander G., Alvaro D., Bergquist A., Björkström N.K., Beuers U., Björnsson E., Boberg K.M., Bowlus C.L., Bragazzi M.C., Carbone M., Chazouillères O., Cheung A., Dalekos G., Eaton J., Eksteen B., Ellinghaus D., Färkkilä M., Festen E.A.M., Floreani A., Franceschet I., Gotthardt D.N., Hirschfield G.M., Hoek B.V., Holm K., Hohenester S., Hov J.R., Imhann F., Invernizzi P., Juran B.D., Lenzen H., Lieb W., Liu J.Z., Marschall H.-U., Marzioni M., Melum E., Milkiewicz P., Pares A., Rupp C., Rust C., Sandford R.N., Schramm C., Schreiber S., Schrumpf E., Silverberg M.S., Srivastava B., Sterneck M., Teufel A., Vallier L., Verheij J., Vila A.V., De Vries B., Zachou K., Chapman R.W., Manns M.P., Pinzani M., Rushbrook S.M., Lazaridis K.N., Franke A., Anderson C.A., Karlsen T.H., Ponsioen C.Y., Weersma R.K. (2018)
      Objective Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic ...

    • Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta 

      Heidrich, B.; Yurdaydin, C.; Kabaçam, G.; Ratsch, B. A.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Tabak, F.; Yalcin, K.; Gürel, S.; Zeuzem, S.; Cornberg, M.; Bock, C. T.; Manns, M. P.; Wedemeyer, H. (2014)
      Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ...

    • Prognostic significance of flow cytometry MRD log reduction during induction treatment of childhood ALL 

      Ampatzidou M., Paterakis G., Vasdekis V., Papadhimitriou S.I., Papadakis V., Vassilopoulos G., Polychronopoulou S. (2019)
      [No abstract available]

    • Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy 

      Pölzl G., Altenberger J., Baholli L., Beltrán P., Borbély A., Comin-Colet J., Delgado J.F., Fedele F., Fontana A., Fruhwald F., Giamouzis G., Giannakoulas G., Garcia-González M.J., Gustafsson F., Kaikkonen K., Kivikko M., Kubica J., von Lewinski D., Löfman I., Malfatto G., Manito N., Martínez-Sellés M., Masip J., Merkely B., Morandi F., Mølgaard H., Oliva F., Pantev E., Papp Z., Perna G.P., Pfister R., Piazza V., Bover R., Rangel-Sousa D., Recio-Mayoral A., Reinecke A., Rieth A., Sarapohja T., Schmidt G., Seidel M., Störk S., Vrtovec B., Wikström G., Yerly P., Pollesello P. (2017)
      Patients in the latest stages of heart failure are severely compromised, with poor quality of life and frequent hospitalizations. Heart transplantation and left ventricular assist device implantation are viable options ...

    • TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting 

      Fountzilas G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., Lakis S., Bobos M., Poulios C., Sotiropoulou M., Lyberopoulou A., Gogas H., Pentheroudakis G., Pectasides D., Koutras A., Christodoulou C., Papandreou C., Samantas E., Papakostas P., Kosmidis P., Bafaloukos D., Karanikiotis C., Dimopoulos M.-A., Kotoula V. (2016)
      Background: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- ...

    • Transcutaneous carbon dioxide monitoring as a predictive tool for all-cause 6-month mortality after acute pulmonary embolism 

      Kotsiou O.S., Karadontas V., Daniil Z., Zakynthinos E., Gourgoulianis K.I. (2019)
      Background: Pulmonary embolism (PE) frequently remains undiagnosed. The partial pressure of carbon dioxide (PaCO2), a surrogate of dead-space ventilation, is useful in the evaluation of the degree of pulmonary artery ...